Aims Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart
failure and for death in patients with symptomatic heart failure. However, trials investigating …

Aims To investigate the seroconversion following first and second COVID‐19 vaccination in
people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination …

Background Recent studies in animal models have shown a link between ingestion of dietary
phosphatidylcholine (PC), choline, l-carnitine and cardiovascular risk. Intestinal microbiota-…

OBJECTIVE To investigate the safety and feasibility of 3 nonconsecutive days of intermittent
fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes. …

Background Sodium glucose cotransporter 2 (SGLT2) inhibitors are established antidiabetic
drugs with proven cardiovascular benefit. Although growing evidence suggests beneficial …

Metabolic syndrome is associated with disturbances in gut microbiota composition. We aimed
to investigate the effect of Lactobacillus casei Shirota (LcS) on gut microbiota composition, …

As people with diabetes are considered a high-risk population in the coronavirus disease
2019 (COVID-19) pandemic scenario, they are globally prioritized in COVID-19 vaccine policy. …

Background Patients with rapid progression of carotid intima media thickness (CIMT) were
shown to have a higher future risk for cardiovascular events. The aim of this study was to …

Background/objectives Alternate day fasting (ADF) is a subtype of intermittent fasting and is
defined as a continuous sequence of a fast day (100% energy restriction, zero calories) and …

Background SGTL2-inhibitors are a cornerstone in the treatment of heart failure, but data on
patients with acute myocardial infarction (AMI) is limited. The EMMY trial was the first to …